IR@PKUHSC  > 北京大学第一临床医学院
学科主题临床医学
Comparison of Treatment Safety and Patient Survival in Elderly versus Nonelderly Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib Combined with Transarterial Chemoembolization: A Propensity Score Matching Study
Hu, Hao1; Duan, Zhenhua2; Long, Xiaoran3; Hertzanu, Yancu4; Tong, Xiaoqiang5; Xu, Xiaoquan6; Shi, Haibin1; Liu, Sheng1; Yang, Zhengqiang1
刊名PLOS ONE
2015-02-17
DOI10.1371/journal.pone.0117168
10期:2
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Multidisciplinary Sciences
研究领域[WOS]Science & Technology - Other Topics
关键词[WOS]TRANS-ARTERIAL CHEMOEMBOLIZATION ; PHASE-II ; MANAGEMENT ; PROGNOSIS ; OUTCOMES
英文摘要

Aims

This retrospective study was carried out to compare the outcomes between elderly (>= 70 years of age) and nonelderly patients (< 70 years of age) with advanced hepatocellular carcinoma (HCC) who received sorafenib combined with transarterial chemoembolization (TACE).

Methods

88 patients with a confirmed diagnosis of advanced HCC were enrolled in this study. Of these, 24 elderly patients were matched with 48 nonelderly patients at a 1:2 ratio using propensity score matching to minimize selection bias. The related adverse events and survival benefits were compared between the two groups.

Results

Sorafenib combined with TACE was equally well tolerated in both age groups, and grade 3 or 4 adverse events were similarly observed in 54.2% of elderly and 50.0% of nonelderly patients (P = 0.739). There were no significant differences in survival time between the elderly and nonelderly patients (P = 0.876). Significant prognostic factors for overall survival as identified by multivariate analysis were the Child-Pugh score and portal vein invasion.

Conclusions

Sorafenib combined with TACE may be well tolerated and effective in elderly patients with advanced HCC. Age alone is not a parameter for the treatment of advanced HCC patients.

语种英语
WOS记录号WOS:000350322700029
引用统计
被引频次:4[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/56293
专题北京大学第一临床医学院
北京大学第一临床医学院_介入血管外科
作者单位1.Ben Gurion Univ Negev, Fac Hlth Sci, Beer Sheva, Israel
2.Chengdu Ctr Dis Control & Prevent, Chengdu, Peoples R China
3.Anhui Med Univ, Sch Pharm, Hefei, Peoples R China
4.Nanjing Med Univ, Affiliated Hosp 1, Dept Intervent Radiol, Nanjing, Jiangsu, Peoples R China
5.Peking Univ, Hosp 1, Dept Intervent Radiol & Vasc Surg, Beijing 100871, Peoples R China
6.Nanjing Med Univ, Affiliated Hosp 1, Dept Radiol, Nanjing, Jiangsu, Peoples R China
推荐引用方式
GB/T 7714
Hu, Hao,Duan, Zhenhua,Long, Xiaoran,et al. Comparison of Treatment Safety and Patient Survival in Elderly versus Nonelderly Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib Combined with Transarterial Chemoembolization: A Propensity Score Matching Study[J]. PLOS ONE,2015,10(2).
APA Hu, Hao.,Duan, Zhenhua.,Long, Xiaoran.,Hertzanu, Yancu.,Tong, Xiaoqiang.,...&Yang, Zhengqiang.(2015).Comparison of Treatment Safety and Patient Survival in Elderly versus Nonelderly Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib Combined with Transarterial Chemoembolization: A Propensity Score Matching Study.PLOS ONE,10(2).
MLA Hu, Hao,et al."Comparison of Treatment Safety and Patient Survival in Elderly versus Nonelderly Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib Combined with Transarterial Chemoembolization: A Propensity Score Matching Study".PLOS ONE 10.2(2015).
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Hu, Hao]的文章
[Duan, Zhenhua]的文章
[Long, Xiaoran]的文章
百度学术
百度学术中相似的文章
[Hu, Hao]的文章
[Duan, Zhenhua]的文章
[Long, Xiaoran]的文章
必应学术
必应学术中相似的文章
[Hu, Hao]的文章
[Duan, Zhenhua]的文章
[Long, Xiaoran]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。